Alcohol Consumption Among Adults With a Cancer Diagnosis in the All of Us Research Program.

ABSTRACT

Importance Alcohol consumption is associated with adverse oncologic and treatment outcomes among individuals with a diagnosis of cancer. As a key modifiable behavioral factor, alcohol consumption patterns among cancer survivors, especially during treatment, remain underexplored in the United States. Objective: To comprehensively characterize alcohol consumption patterns among US cancer survivors. Design, Setting, and Participants: This cross-sectional study used data from May 6, 2018, to January 1, 2022, from the National Institutes of Health All of Us Research Program, a diverse US cohort with electronic health record (EHR) linkage, and included 15 199 participants who reported a cancer diagnosis and 1839 patients among a subset with EHR data who underwent treatment within the past year of the baseline survey. Data analysis was performed from October 1, 2022, to January 31, 2023. Main Outcomes and Measures: Prevalence of current drinking and of risky drinking behaviors, including exceeding moderate drinking (>2 drinks on a typical drinking day), binge drinking (≥6 drinks on 1 occasion), and hazardous drinking (Alcohol Use Disorders Identification Test-Consumption [AUDIT-C] score ≥3 for women or ≥4 for men). Results: This study included 15 199 adults (mean [SD] age at baseline, 63.1 [13.0] years; 9508 women [62.6%]) with a cancer diagnosis. Overall, 11 815 cancer survivors (77.7%) were current drinkers. Among current drinkers, 1541 (13.0%) exceeded moderate drinking, 2812 (23.8%) reported binge drinking, and 4527 (38.3%) engaged in hazardous drinking. After multivariable adjustment, survivors who were younger than 65 years, men, or of Hispanic ethnicity or who received a diagnosis before 18 years of age or ever smoked were more likely to exceed moderate drinking (aged <50 years odds ratio [OR], 2.90 [95% CI, 2.41-3.48]; aged 50-64 years OR, 1.84 [95% CI, 1.58-2.15]; men OR, 2.38 [95% CI, 2.09-2.72]; Hispanic ethnicity OR, 1.31 [95% CI, 1.04-1.64]; aged <18 years at diagnosis OR, 1.52 [95% CI, 1.04-2.24]; former smokers OR, 2.46 [95% CI, 2.16-2.79]; current smokers OR, 4.14 [95% CI, 3.40-5.04]) or binge drink (aged <50 years OR, 4.46 [95% CI, 3.85-5.15]; aged 50-64 years OR, 2.15 [95% CI, 1.90-2.43]; men OR, 2.10 [95% CI, 1.89-2.34]; Hispanic ethnicity OR, 1.31 [95% CI, 1.09-1.58]; aged <18 years at diagnosis OR, 1.71 [95% CI, 1.24-2.35]; former smokers OR, 1.69 [95% CI, 1.53-1.87]; current smokers OR, 2.27 [95% CI, 1.91-2.71]). Survivors with cancer diagnosed before 18 years of age or who ever smoked were more likely to be hazardous drinkers (aged <18 years at diagnosis OR, 1.52 [95% CI, 1.11-2.08]; former smokers OR, 1.83 [95% CI, 1.68-1.99]; current smokers OR, 2.13 [95% CI, 1.79-2.53]). Of 1839 survivors receiving treatment as captured in the EHR, 1405 (76.4%) were current drinkers, and among these, 170 (12.1%) exceeded moderate drinking, 329 (23.4%) reported binge drinking, and 540 (38.4%) engaged in hazardous drinking, with similar prevalence across different types of cancer treatment. Conclusions and Relevance This cross-sectional study of a diverse US cohort suggests that alcohol consumption and risky drinking behaviors were common among cancer survivors, even among individuals receiving treatment. Given the adverse treatment and oncologic outcomes associated with alcohol consumption, additional research and implementation studies are critical in addressing this emerging concern among cancer survivors.